Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Armodafinil - Teva Pharmaceutical Industries

Next Previous
Drug Profile

Armodafinil - Teva Pharmaceutical Industries

Alternative Names: CEP-10953; Nuvigil; R-modafinil

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon
  • Developer Cephalon; Lindner Center of HOPE; Oncotherapeutics.; Teva Pharmaceutical Industries
  • Class Acetamides; Benzhydryl compounds; Sleep disorder therapies; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor agonists; Biogenic amine receptor agonists; Catecholamine receptor agonists; Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypersomnia
  • Phase III Eating disorders; Fatigue
  • Discontinued Bipolar depression; Schizophrenia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypersomnia(In adolescents, In children) in Finland (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypersomnia(In adolescents, In children) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top